COSMEGEN

This brand name is authorized in United States. It is also authorized in Canada, Estonia, France, Japan, Malta, New Zealand, Romania, UK.

Active ingredients

The drug COSMEGEN contains one active pharmaceutical ingredient (API):

1	Dactinomycin UNII 1CC1JFE158 - DACTINOMYCIN
	Dactinomycin is an antineoplastic antibiotic derived from Streptomyces parvullus. Stable complexes are formed with DNA through intercalation and DNA-dependent RNA synthesis is selectively inhibited. Protein and DNA synthesis are inhibited to a lesser extent.
	Read more about Dactinomycin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
COSMEGEN Lyophilised powder for solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01DA01	Dactinomycin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01D Cytotoxic antibiotics and related substances → L01DA Actinomycines
Discover more medicines within L01DA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	00213071
EE	Ravimiamet	1611188
FR	Base de données publique des médicaments	66507634
GB	Medicines & Healthcare Products Regulatory Agency	44967
JP	医薬品医療機器総合機構	4233400D1036
MT	Medicines Authority	AA135/00202
NZ	Medicines and Medical Devices Safety Authority	488
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69339001
US	FDA, National Drug Code	55292-811